TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC

KRASG12C is one of the most common mutations detected in non-small cell lung cancer (NSCLC) patients, and it is a marker of poor prognosis. The first FDA-approved KRASG12C inhibitors, sotorasib and adagrasib, have been an enormous breakthrough for patients with KRASG12C</s...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Salvina Laura Tammaccaro, Philippe Prigent, Jean-Christophe Le Bail, Odette Dos-Santos, Laurent Dassencourt, Myriam Eskandar, Armelle Buzy, Olivier Venier, Jean-Claude Guillemot, Yaligara Veeranagouda, Michel Didier, Emmanuel Spanakis, Tokuwa Kanno, Matteo Cesaroni, Stephane Mathieu, Luc Canard, Alhassan Casse, Fanny Windenberger, Loreley Calvet, Laurence Noblet, Sukhvinder Sidhu, Laurent Debussche, Jurgen Moll, Iris Valtingojer
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2023-04-01
Rangatū:	Pharmaceuticals
Ngā marau:	YAP1-TEAD resistance KRAS<sup>G12C</sup> NSCLC cell cycle arrest
Urunga tuihono:	https://www.mdpi.com/1424-8247/16/4/553
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

TEAD Inhibitors Sensitize KRAS<sup>G12C</sup> Inhibitors via Dual Cell Cycle Arrest in KRAS<sup>G12C</sup>-Mutant NSCLC

Ngā tūemi rite